Skip to main content
SpringerLink
Log in
Book cover

Clinical Reproductive Medicine and Surgery pp 139–161Cite as

Menopause

  • Chapter
  • First Online:

  • 1967 Accesses

Abstract

Up to one-third of a woman’s lifetime will take place in menopause. This chapter will discuss the physiological changes and symptoms associated with menopause. The clinical management of menopausal symptoms with hormone therapy, nonhormonal medications, and nonmedical treatments will be reviewed. Additionally, we will discuss key clinical trials that examine treatment efficacy and the risks and benefits of various treatment approaches. Lastly, preventive approaches, lifestyle modifications, and national recommendations for supplements such as calcium and vitamin D will be reviewed.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   159.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   209.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. McKinlay SM, Bifano NL, McKinlay JB. Smoking and age at menopause in women. Ann Intern Med. 1985;103(3):350–6.

    PubMed  CAS  Google Scholar 

  2. McKinlay SM. The normal menopause transition; an overview. Maturitas. 1996;23(2):137–45.

    PubMed  CAS  Google Scholar 

  3. Weg RB. Demography. In: Mishell Jr DR, editor. Menopause: physiology and pharmacology. Chicago: Year Book Medical; 1987. p. 23–40.

    Google Scholar 

  4. The World Health Report. Making a difference. Geneva: World Health Organization; 1999.

    Google Scholar 

  5. American Congress of Obstetricians and Gynecologists. http://www.acog.org.

  6. World Health Organization. Research on the menopause on the 1990’s. WHO Technical Report Series 1996, No. 866. Geneva: World Health Organization.

    Google Scholar 

  7. Faddy MJ, Gosden RG. A model conforming the decline in follicle numbers to the age of menopause in women. Hum Reprod. 1996;11(7):1484–6.

    PubMed  CAS  Google Scholar 

  8. Faddy MJ, Gosden RG. A mathematical model of follicle dynamics in the human ovary. Hum Reprod. 1995;10(4):770–5.

    PubMed  CAS  Google Scholar 

  9. Faddy MJ, Gosden RG, Gougeon A, Richardson SJ, Nelson JF. Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. Hum Reprod. 1992;7(10):1342–6.

    PubMed  CAS  Google Scholar 

  10. Johnson J, Canning J, Kaneko T, Pru JK, Tilly JL. Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature. 2004;428:145–50.

    PubMed  CAS  Google Scholar 

  11. Lee H, Selesniemi K, Niikura Y, Niikura T, Klein R, Dombkowski D, et al. Bone marrow transplantation generates immature oocytes and rescues long-term fertility in a preclinical mouse model of chemotherapy-induced premature ovarian failure. J Clin Oncol. 2007;25:3198–204.

    PubMed  CAS  Google Scholar 

  12. McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas. 1992;14(2):103–15.

    PubMed  CAS  Google Scholar 

  13. Rizk DE, Bener A, Ezimokhai M, Hassan MY, Micallef R. The age and symptomatology of natural menopause among United Arab Emirates women. Maturitas. 1998;29(3):197–202.

    PubMed  CAS  Google Scholar 

  14. Randhawa I, Premi HK, Gupta T. The age at menopause in the women of Himachal Pradesh, and the factors affecting the menopause. Indian J Public Health. 1987;31(1):40–4.

    PubMed  CAS  Google Scholar 

  15. Midgette AS, Baron JA. Cigarette smoking and the risk of natural menopause. Epidemiology. 1990;1(6):474–80.

    PubMed  CAS  Google Scholar 

  16. van Asselt KM, Kok HS, van Der Schouw YT, Grobbee DE, te Velde ER, Pearson PL, et al. Current smoking at menopause rather than duration determines the onset of natural menopause. Epidemiology. 2004;15(5):634–9.

    PubMed  Google Scholar 

  17. Picton HM. Activation of follicle development: the primordial follicle. Theriogeneology. 2001;55:1193–210.

    CAS  Google Scholar 

  18. Yuan W, Giudice LC. Programmed cell death in human ovary is a function of follicle and corpus luteum status. J Clin Endocrinol Metab. 1997;82(9):3148–55.

    PubMed  CAS  Google Scholar 

  19. de Bruin JP, Dorland M, Spek ER, Posthuma G, van Haaften M, Looman CW, et al. Ultrastructure of the resting ovarian follicle pool in healthy young women. Biol Reprod. 2002;66(4):1151–60.

    PubMed  Google Scholar 

  20. de Bruin JP, Bovenhuis H, van Noord PAH, Pearson PL, van Arendonk JA, te Velde ER, et al. The role of genetic factors in age at natural menopause. Hum Reprod. 2001;16:2014–8.

    PubMed  Google Scholar 

  21. Torgerson DJ, Thomas RE, Reid DM. Mothers and daughters menopausal ages: is there a link? Eur J Obstet Gynecol Reprod Biol. 1997;74:63–6.

    PubMed  CAS  Google Scholar 

  22. Cramer DW, Xu H, Harlow BL. Family history as a predictor of early menopause. Fertil Steril. 1995;64:740–5.

    PubMed  CAS  Google Scholar 

  23. van Asselt KM, Kok HS, Pearson PL, Dubas JS, Peeters PH, Te Velde ER, et al. Heritability of menopausal age in mothers and daughters. Fertil Steril. 2004;82(5):1348–51.

    PubMed  Google Scholar 

  24. Harlow SD, Gass M, Hall J, Lobo R, Maki P, Rebar RW, et al. Executive summary of stages of reproductive aging workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012;19(4):387–95.

    PubMed  Google Scholar 

  25. Miller HG, Li RM. Measuring hot flashes: summary of a National Institutes of Health workshop. Mayo Clin Proc. 2004;79(6):777–81.

    PubMed  Google Scholar 

  26. Freedman RR. Physiology of hot flashes. Am J Hum Biol. 2001;13(4):453–64.

    PubMed  CAS  Google Scholar 

  27. Mohyi D, Tabassi K, Simon J. Differential diagnosis of hot flashes. Maturitas. 1997;27(3):203–14.

    PubMed  CAS  Google Scholar 

  28. Sonnet S, Wiesner W. Flush symptoms caused by a mesenteric carcinoid without liver metastases. JBR-BTR. 2002;85(5):254–6.

    PubMed  CAS  Google Scholar 

  29. Torvik A. Carcinoid syndrome in a primary tumour of the ovary. Acta Pathol Microbiol Scand. 1960;48:81–8.

    PubMed  CAS  Google Scholar 

  30. Lips CJ, Lentjes EG, Hoppener JW. The spectrum of carcinoid tumours and carcinoid syndromes. Ann Clin Biochem. 2003;40(Pt 6):612–27.

    PubMed  Google Scholar 

  31. Valent P, Sperr WR, Schwartz LB, Horny HP. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. J Allergy Clin Immunol. 2004;114(1):3–11.

    PubMed  CAS  Google Scholar 

  32. Manger WM, Eisenhofer G. Pheochromocytoma: diagnosis and management update. Curr Hypertens Rep. 2004;6(6):477–84.

    PubMed  Google Scholar 

  33. Moley JF. Medullary thyroid cancer. Surg Clin North Am. 1995;75:405–20.

    PubMed  CAS  Google Scholar 

  34. Gertner ME, Kebebew E. Multiple endocrine neoplasia type 2. Curr Treat Options Oncol. 2004;5(4):315–25.

    PubMed  Google Scholar 

  35. Wilkin JK. Quantitative assessment of alcohol-provoked flushing. Arch Dermatol. 1986;122(1):63–5.

    PubMed  CAS  Google Scholar 

  36. Wilkin JK. Effect of nadolol on flushing reactions in rosacea. J Am Acad Dermatol. 1989;20(2 Pt 1):202–5.

    PubMed  CAS  Google Scholar 

  37. Baker A, Simpson S, Dawson D. Sleep disruption and mood changes associated with menopause. J Psychosom Res. 1997;43(4):359–69.

    PubMed  CAS  Google Scholar 

  38. Owens JF, Matthews KA. Sleep disturbance in healthy middle-aged women. Maturitas. 1998;30:41–50.

    PubMed  CAS  Google Scholar 

  39. Erlik Y, Tataryn IV, Meldrum DR, Lomax P, Bajorek JG, Judd HL. Association of waking episodes with menopausal hot flushes. JAMA. 1981;245(17):1741–4.

    PubMed  CAS  Google Scholar 

  40. Stone AB, Pearlstein TB. Evaluation and treatment of changes in mood, sleep, and sexual functioning associated with menopause. Obstet Gynecol Clin N Am. 1994;21:391–403.

    CAS  Google Scholar 

  41. Freedman RR, Roehrs TA. Lack of sleep disturbance from menopausal hot flashes. Fertil Steril. 2004;82(1):138–44.

    PubMed  Google Scholar 

  42. Liu JH, Reape KZ, Hait HI. Synthetic conjugated estrogens-B and postmenopausal nocturnal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol. 2012;119(1):78–84.

    PubMed  CAS  Google Scholar 

  43. MacGregor EA. Oestrogen and attacks of migraine with and without aura. Lancet Neurol. 2004;3(6):354–61.

    PubMed  CAS  Google Scholar 

  44. Silberstein SD. Headache and female hormones: what you need to know. Curr Opin Neurol. 2001;14(3):323–3.

    PubMed  CAS  Google Scholar 

  45. Bono G, Neri I, Granella F, Genazzani AR, Facchinetti F. Characteristics of headache at menopause: a clinico-epidemiologic study. Maturitas. 1993;17(1):31–7.

    Google Scholar 

  46. Wang SJ, Fuh JL, Lu SR, Juang KD, Wang PH. Migraine prevalence during menopausal transition. Headache. 2003;43(5):470–8.

    PubMed  Google Scholar 

  47. Falconer C, Ekman-Ordeberg G, Ulmsten U, Westergren-Thorsson G, Barchan K, Malmstrom A. Changes in paraurethral connective tissue at menopause are counteracted by estrogen. Maturitas. 1996;24(3):197–204.

    PubMed  CAS  Google Scholar 

  48. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med. 1993;329(11):753–6.

    PubMed  CAS  Google Scholar 

  49. Brown JS, Vittinghoff E, Kanaya AM, Agarwal SK, Hulley S, Foxman B, et al. Urinary tract infections in postmenopausal women: effect of hormone therapy and risk factors. Obstet Gynecol. 2001;98(6):1045–52.

    PubMed  CAS  Google Scholar 

  50. Caillouette JC, Sharp CF Jr, Zimmerman GJ, Roy S. Vaginal pH as a marker for bacterial pathogens and menopausal status. Am J Obstet Gynecol. 1997;176(6):1270–5; discussion 1275–7.

    Google Scholar 

  51. Roy S, Caillouette JC, Roy T, Faden JS. Vaginal pH is similar to follicle-stimulating hormone for menopause diagnosis. Am J Obstet Gynecol. 2004;190(5):1272–7.

    PubMed  CAS  Google Scholar 

  52. Melton III LJ, Chrischilles EA, Cooper C, Lane AW, Riggs BL. Perspective: how many women have osteoporosis? J Bone Miner Res. 1992;7:1005–10.

    PubMed  Google Scholar 

  53. National Osteoporosis Foundation. Osteoporosis: disease statistics: “fast facts.” http://www.nof.org/osteoporosis/stats.htm. Accessed 6 Dec 2004.

  54. Melton III LJ, Thamer M, Ray NF, Chan JK, Chesnut III CH, Einhorn TA, et al. Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997;12:16–23.

    PubMed  Google Scholar 

  55. Ahlborg HG, Johnell O, Nilsson BE, Jeppsson S, Rannevik G, Karlsson MK. Bone loss in relation to menopause: a prospective study during 16 years. Bone. 2001;28(3):327–31.

    PubMed  CAS  Google Scholar 

  56. Riggs BL, Melton III LJ. Involutional osteoporosis. N Engl J Med. 1986;314(26):1676–86.

    PubMed  CAS  Google Scholar 

  57. Nevitt MC, Ettinger B, Black DM, Stone K, Jamal SA, Ensrud K, et al. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med. 1998;128:793–800.

    PubMed  CAS  Google Scholar 

  58. Forsen L, Sogaard AJ, Meyer HE, Edna T, Kopjar B. Survival after hip fracture: short- and long-term excess mortality according to age and gender. Osteoporos Int. 1999;10:73–8.

    PubMed  CAS  Google Scholar 

  59. Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ. 2003;81(9):646–56.

    PubMed  Google Scholar 

  60. American Heart Association. 1997 Heart and stroke facts: statistical update. Dallas, TX: American Heart Association; 1996.

    Google Scholar 

  61. Eaker ED, Chesebro JH, Sacks FM, Wenger NK, Whisnant JP, Winston M. Cardiovascular disease in women. Circulation. 1993;88(4 Pt 1):1999–2009.

    PubMed  CAS  Google Scholar 

  62. Gallup Poll. Coronary heart disease: Women’s Heart Health Initiative. 1995. American Medical Women’s Association. http://www.amwa-doc.org/Education/gallup.htm.

  63. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation. 1994;89(3):1333–445.

    Google Scholar 

  64. Gorodeski GI. Impact of the menopause on the epidemiology and risk factors of coronary artery heart disease in women. Exp Gerontol. 1994;29(3–4):357–75.

    PubMed  CAS  Google Scholar 

  65. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med. 1987;316(18):1105–10.

    PubMed  CAS  Google Scholar 

  66. American College of Obstetricians and Gynecologists Women’s Health Care Physicians. Executive summary. Hormone therapy. Obstet Gynecol. 2004;104:S1–4.

    Google Scholar 

  67. North American Menopause Society Report. Menopause. 2003;10:6–12.

    Google Scholar 

  68. http://www.fda.gov/cder/guidance/5412dft.doc. Accessed 12 Sept 2004. This guidance was developed by the Division of Reproductive and Urologic Drug Products (DRUDP) in the Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA).

  69. North American Menopause Society. The 2012 hormone therapy position statement. Menopause. 2012;19(3):257–71.

    Google Scholar 

  70. Hays J, Hunt JR, Hubbell FA, Anderson GL, Limacher M, Allen C, et al. The Women’s Health Initiative recruitment methods and results. Ann Epidemiol. 2003;13(9 Suppl):S18–77.

    PubMed  Google Scholar 

  71. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33.

    Google Scholar 

  72. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701–12.

    PubMed  CAS  Google Scholar 

  73. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA. 2002;288(7):872–81.

    PubMed  CAS  Google Scholar 

  74. Grady D. Postmenopausal hormones–therapy for symptoms only. N Engl J Med. 2003;348(19):1835–7.

    PubMed  Google Scholar 

  75. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297:1465–77.

    PubMed  CAS  Google Scholar 

  76. Prentice RL, Langer R, Stefanick ML, Howard BV, Pettinger M, Anderson G, et al. Women’s Health Initiative Investigators. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women’s Health Initiative clinical trial. Am J Epidemol. 2005;162:404–14.

    Google Scholar 

  77. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280(7):605–13.

    PubMed  CAS  Google Scholar 

  78. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al. HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288(1):49–57. Erratum in JAMA. 2002;288(9):1064.

    Google Scholar 

  79. Beral V. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362(9382):419–27.

    Google Scholar 

  80. Mashchak CA, Lobo RA, Dozono-Takano R, Eggena P, Nakamura RM, Brenner PF, et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol. 1982;144(5):511–8.

    PubMed  CAS  Google Scholar 

  81. Pickar JH, Yeh IT, Wheeler JE, Cunnane MF, Speroff L. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results. Fertil Steril. 2003;80(5):1234–40.

    PubMed  Google Scholar 

  82. Baker VL. Alternatives to oral estrogen replacement. Transdermal patches, percutaneous gels, vaginal creams and rings, implants, other methods of delivery. Obstet Gynecol Clin North Am. 1994;21(2):271–97.

    PubMed  CAS  Google Scholar 

  83. Menostar—a low-dose estrogen patch for osteoporosis. Med Lett Drugs Ther. 2004;46(1190):69–70.

    Google Scholar 

  84. Archer DF; EstroGel Study Group. Percutaneous 17beta-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women. Menopause. 2003;10(6):516–21.

    Google Scholar 

  85. Fontana A, Delmas PD. Selective estrogen receptors modulators in the prevention and treatment of postmenopausal osteoporosis. Endocrinol Metab Clin North Am. 2003;32(1):219–32.

    PubMed  CAS  Google Scholar 

  86. Khovidhunkit W, Shoback DM. Clinical effects of raloxifene hydrochloride in women. Ann Intern Med. 1999;130(5):431–9.

    PubMed  CAS  Google Scholar 

  87. Jensen EV, Khan SA. A two-site model for antiestrogen action. Mech Ageing Dev. 2004;125(10–11):679–82.

    PubMed  CAS  Google Scholar 

  88. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371–88.

    PubMed  CAS  Google Scholar 

  89. Black LJ, Jones CD, Falcone JF. Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci. 1983;32(9):1031–6.

    PubMed  CAS  Google Scholar 

  90. Black LJ, Jones CD, Clark JH, Clemens JA. A unique antiestrogen displaying high affinity for estrogen receptors, negligible estrogenic activity and near-total estrogen antagonism in vivo [Abstract]. Breast Cancer Res Treat. 1982;2:279–9.

    Google Scholar 

  91. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337:1641–7.

    PubMed  CAS  Google Scholar 

  92. Sambrook PN, Geusens P, Ribot C, Solimano JA, Ferrer-Barriendos J, Gaines K, et al. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International. J Intern Med. 2004;255(4):503–11.

    PubMed  CAS  Google Scholar 

  93. Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002;87(3):985–92.

    PubMed  CAS  Google Scholar 

  94. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282(7):637–45. Erratum in JAMA. 1999;282(22):2124.

    Google Scholar 

  95. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999;281(23):2189–97. Erratum in JAMA. 1999;282(22):2124.

    Google Scholar 

  96. Vogel VG, Constantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes. The NSABP study of tamoxifen and raloxifene (STAR) P-2 Trial. JAMA. 2006;295(23):2727–41.

    PubMed  CAS  Google Scholar 

  97. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA. 1998;279(18):1445–51.

    PubMed  CAS  Google Scholar 

  98. Mijatovic V, van der Mooren MJ, Kenemans P, de Valk-de Roo GW, Netelenbos C. Raloxifene lowers serum lipoprotein(A) in healthy postmenopausal women: a randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens. Menopause. 1999;6(2):134–7.

    PubMed  CAS  Google Scholar 

  99. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355(2):125–37.

    PubMed  CAS  Google Scholar 

  100. Kloosterboer HJ. Tissue-selectivity: the mechanism of action of tibolone. Maturitas. 2004;48 Suppl 1Suppl 1:S30–40.

    PubMed  CAS  Google Scholar 

  101. Gambacciani M, Ciaponi M, Cappagli B, Monteleone P, Benussi C, Bevilacqua G, et al. A longitudinal evaluation of the effect of two doses of tibolone on bone density and metabolism in early postmenopausal women. Gynecol Endocrinol. 2004;18(1):9–16.

    PubMed  CAS  Google Scholar 

  102. Palacios S, Menendez C, Jurado AR, Castano R, Vargas JC. Changes in sex behaviour after menopause: effects of tibolone. Maturitas. 1995;22(2):155–61.

    PubMed  CAS  Google Scholar 

  103. Kokcu A, Cetinkaya MB, Yanik F, Alper T, Malatyalioglu E. The comparison of effects of tibolone and conjugated estrogen-medroxyprogesterone acetate therapy on sexual performance in postmenopausal women. Maturitas. 2000;36(1):75–80.

    PubMed  CAS  Google Scholar 

  104. Beral V. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362(9382):419–27. Erratum in Lancet. 2003;362(9390):1160.

    Google Scholar 

  105. Pantidou A, Kaplanis K, Chrissogonidis I, Destouni C. Mammographic changes during postmenopausal hormonal replacement therapy with tibolone. Eur J Gynaecol Oncol. 2004;25(4):493–4.

    PubMed  CAS  Google Scholar 

  106. Kutlu T, Ficicioglu C, Basaran T, Basaran E, Topaloglu T. Mammographic breast density changes after 1 year of tibolone use. Maturitas. 2004;48(2):133–6.

    PubMed  CAS  Google Scholar 

  107. Simon J, Klaiber E, Wiita B, Bowen A, Yang HM. Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women. Menopause. 1999;6:138–46.

    PubMed  CAS  Google Scholar 

  108. Liu J, Allgood A, Derogatis LR, Swanson S, O’Mahony M, Nedoss B, et al. Safety and efficacy of low-dose esterified estrogens and methyltestosterone, alone or combined, for the treatment of hot flashes in menopausal women: a randomized, double-blind, placebo-controlled study. Fertil Steril. 2011;95(1):366–8.

    PubMed  CAS  Google Scholar 

  109. Zumoff B, Strain GW, Miller LK, Rosner W. Twenty-four hour mean plasma testosterone concentration declines with age in normal premenopausal women. J Clin Endocrinol Metab. 1995;80:1429–30.

    PubMed  CAS  Google Scholar 

  110. Sowers MR, Jannausch M, McConnell D, Little R, Greendale GA, Finkelstein JS, et al. Hormone predictors of bone mineral density changes during the menopausal transition. J Clin Endocrinol Metab. 2006;91:1261–7.

    PubMed  CAS  Google Scholar 

  111. Shifren JL, Braunstein GD, Simon JA, Casson PR, Buster JE, Redmond GP, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med. 2000;343:682–8.

    PubMed  CAS  Google Scholar 

  112. Braunstein GD, Sundwall DA, Katz M, Shifren JL, Buster JE, Simon JA, et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized placebo-controlled trial. Arch Intern Med. 2005;165:1582–9.

    PubMed  CAS  Google Scholar 

  113. Buster JE, Kingsberg SA, Aguirre O, Brown C, Breaux JG, Buch A, et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol. 2005;105:944–52.

    PubMed  CAS  Google Scholar 

  114. Simon J, Braunstein G, Nachtigall L, Utian W, Katz M, Miller S, et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab. 2005;90:5226–33.

    PubMed  CAS  Google Scholar 

  115. Parra RO, Gregory JG. Treatment of post-orchiectomy hot flashes with transdermal administration of clonidine. J Urol. 1990;143(4):753–4.

    PubMed  CAS  Google Scholar 

  116. Nagamani M, Kelver ME, Smith ER. Treatment of menopausal hot flashes with transdermal administration of clonidine. Am J Obstet Gynecol. 1987;156(3):561–5.

    PubMed  CAS  Google Scholar 

  117. Speroff L, Gass M, Constantine G, Olivier S; Study 315 Investigators. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol. 2008;111(1):77–87.

    Google Scholar 

  118. Magnus L. Nonepileptic uses of gabapentin. Epilepsia. 1999;40 Suppl 6:S66–72; discussion S73–4.

    Google Scholar 

  119. Guttuso Jr T, Kurlan R, McDermott MP, Kieburtz K. Gabapentin’s effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol. 2003;101(2):337–45.

    PubMed  CAS  Google Scholar 

  120. Pinkerton J. SV20. 23rd Annual Meeting of the North American Menopause Society 3–6 Oct 2012, Orlando, FL. Menopause 2012;19(12):1365–404.

    Google Scholar 

  121. Freedman RR, Woodward S. Behavioral treatment of menopausal hot flushes: evaluation by ambulatory monitoring. Am J Obstet Gynecol. 1992;167(2):436–9.

    PubMed  CAS  Google Scholar 

  122. Heaney RP, Recker RR, Stegman MR, Moy AJ. Effect of age on calcium absorption in postmenopausal women. Am J Clin Nutr. 2004;80(4):998–1002.

    Google Scholar 

  123. Nordin BE, Need AG, Morris HA, O’Loughlin PD, Horowitz M. Effect of age on calcium absorption in postmenopausal women. Am J Clin Nutr. 2004;80(4):998–1002.

    PubMed  CAS  Google Scholar 

  124. Committee to Review Dietary Reference Intakes for Vitamin D and Calcium, Food and Nutrition Board, Institute of Medicine, Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academy Press; 2010.

    Google Scholar 

  125. Weaver CM, Proulx WR, Heaney R. Choices for achieving adequate dietary calcium with a vegetarian diet. Am J Clin Nutr. 1999;70(3 Suppl):543S–8.

    PubMed  CAS  Google Scholar 

  126. Heller HJ, Greer LG, Haynes SD, Poindexter JR, Pak CY. Pharmacokinetic and pharmacodynamic comparison of two ­calcium supplements in postmenopausal women. J Clin Pharmacol. 2000;40(11):1237–44. Erratum J Clin Pharmacol. 2001;41(1):116.

    Google Scholar 

  127. Heller HJ, Stewart A, Haynes S, Pak CY. Pharmacokinetics of ­calcium absorption from two commercial calcium supplements. J Clin Pharmacol. 1999;39(11):1151–4.

    PubMed  CAS  Google Scholar 

  128. Heaney RP, Dowell SD, Bierman J, Hale CA, Bendich A. Absorbability and cost effectiveness in calcium supplementation. J Am Coll Nutr. 2001;20(3):239–46.

    PubMed  CAS  Google Scholar 

  129. Institute of Medicine, Food and Nutrition Board. Dietary reference intakes for calcium and vitamin D. Washington, DC: National Academy Press; 2010.

    Google Scholar 

  130. Asikainen TM, Kukkonen-Harjula K, Miilunpalo S. Exercise for health for early postmenopausal women: a systematic review of randomised controlled trials. Sports Med. 2004;34(11):753–78.

    PubMed  Google Scholar 

  131. Fuchs CS, Stampfer MJ, Colditz GA, Giovannucci EL, Manson JE, Kawachi I, et al. Alcohol consumption and mortality among women. N Engl J Med. 1995;332(19):1245–50. Erratum N Engl J Med. 1997;336(7):523.

    Google Scholar 

  132. Singletary KW, Gapstur SM. Alcohol and breast cancer: review of epidemiologic and experimental evidence and potential mechanisms. JAMA. 2001;286(17):2143–51.

    PubMed  CAS  Google Scholar 

  133. Kam IW, Dennehy CE, Tsourounis C. Dietary supplement use among menopausal women attending a San Francisco health conference. Menopause. 2002;9(1):72–8.

    PubMed  Google Scholar 

  134. Adams C, Cannell S. Women’s beliefs about “natural” hormones and natural hormone replacement therapy. Menopause. 2001;8(6):433–40.

    PubMed  CAS  Google Scholar 

  135. Gokhale L, Sturdee DW, Parsons AD. The use of food supplements among women attending menopause clinics in the West Midlands. J Br Menopause Soc. 2003;9(1):32–5.

    PubMed  Google Scholar 

  136. Mahady GB, Parrot J, Lee C, Yun GS, Dan A. Botanical dietary supplement use in peri- and postmenopausal women. Menopause. 2003;10(1):65–72.

    PubMed  Google Scholar 

  137. Kronenberg F, Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med. 2002;137(10):805–13.

    PubMed  Google Scholar 

  138. Krebs EE, Ensrud KE, MacDonald R, Wilt TJ. Phytoestrogens for treatment of menopausal symptoms: a systematic review. Obstet Gynecol. 2004;104(4):824–36.

    PubMed  CAS  Google Scholar 

  139. North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause. 2004;11(1):11–33.

    Google Scholar 

  140. Leonetti HB, Longo S, Anasti JN. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol. 1999;94(2):225–8.

    PubMed  CAS  Google Scholar 

  141. Komesaroff PA, Black CV, Cable V, Sudhir K. Effects of wild yam extract on menopausal symptoms, lipids and sex hormones in healthy menopausal women. Climacteric. 2001;4(2):144–50.

    PubMed  CAS  Google Scholar 

  142. Wren BG, Champion SM, Willetts K, Manga RZ, Eden JA. Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal women. Menopause. 2003;10(1):13–8.

    PubMed  Google Scholar 

  143. Dong H, Ludicke F, Comte I, Campana A, Graff P, Bischof P. An exploratory pilot study of acupuncture on the quality of life and reproductive hormone secretion in menopausal women. J Altern Complement Med. 2001;7(6):651–8.

    PubMed  CAS  Google Scholar 

  144. Porzio G, Trapasso T, Martelli S, Sallusti E, Piccone C, Mattei A, et al. Acupuncture in the treatment of menopause-related symptoms in women taking tamoxifen. Tumori. 2002;88(2):128–30.

    PubMed  Google Scholar 

  145. Wyon Y, Wijma K, Nedstrand E, Hammar M. A comparison of acupuncture and oral estradiol treatment of vasomotor symptoms in postmenopausal women. Climacteric. 2004;7(2):153–64.

    PubMed  CAS  Google Scholar 

  146. Sandberg M, Wijma K, Wyon Y, Nedstrand E, Hammar M. Effects of electro-acupuncture on psychological distress in ­postmenopausal women. Complement Ther Med. 2002;10(3):161–9.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Reproductive Biology and Obstetrics and Gynecology, University Hospitals MacDonald Women’s Hospital, 11100 Euclid Avenue, Cleveland, OH, 44106, USA

    James H. Liu MD

  2. Department of Reproductive Endocrinology, RMA of Texas, San Antonio, TX, USA

    Francisco Arredondo MD, MPH

Authors
  1. James H. Liu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francisco Arredondo MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James H. Liu MD .

Editor information

Editors and Affiliations

  1. Cleveland Clinic, Ob/Gyn & Women's Health Institute, Euclid Ave 9500, Cleveland, 44195, Ohio, USA

    Tommaso Falcone

  2. Duke University Medical Center, Duke University School of Medicine, Department of Obstetrics and Gynecology, Erwin Rd 2301, Durham, 27705, North Carolina, USA

    William W. Hurd

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Liu, J.H., Arredondo, F. (2013). Menopause. In: Falcone, T., Hurd, W. (eds) Clinical Reproductive Medicine and Surgery. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6837-0_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-6837-0_10

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-6836-3

  • Online ISBN: 978-1-4614-6837-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation